Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.39 |
| ▸ | PTGES | O14684 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214646 | 1.00 | S1PR1 (0.41) | S1PR1ALOX5PTGESKDM4EMAPT | |
| SCHEMBL3131973 | 0.82 | S1PR1 (0.45) | S1PR1ALOX5PTGESKDM4EMAPT | |
| SCHEMBL4212480 | 0.81 | S1PR1 (0.39) | S1PR1ALOX5PTGESKDM4EMAPT | |
| SCHEMBL3121654 | 0.81 | S1PR1 (0.44) | S1PR1ALOX5PTGESKDM4EMAPT | |
| SCHEMBL2755709 | 0.79 | S1PR1 (0.41) | S1PR1ALOX5MAPT | |
| SCHEMBL207601 | 0.79 | S1PR1 (0.41) | S1PR1ALOX5MAPT | |
| SCHEMBL206134 | 0.76 | MEN1 (0.56) | MAPTMAPK1 | |
| SCHEMBL3128737 | 0.76 | MEN1 (0.56) | MAPTMAPK1 | |
| SCHEMBL208681 | 0.75 | ALOX5 (0.46) | S1PR1ALOX5PTGESMAPTMAPK1 | |
| SCHEMBL206216 | 0.75 | S1PR1 (0.47) | S1PR1ALOX5PTGESMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | S1PR1 3564/4885ALOX5 3440/4885PTGES 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.